Nasus Pharma announces expanded agreement to support NS002

Nasus Pharma (NSRX) announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup (ATR) to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma’s intranasal powder epinephrine product candidate. “This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002’s path to market while reducing development risks.”